Mount Sinai Is First in "New York" to Study a Brain-Computer Interface Designed to Record
Mount Sinai-led study identifies type of heart failure for which device may be most useful
A multidisciplinary team of neurosurgeons and neuroscientists from the Icahn School of Medicine at Mount Sinai are the first in New York to study a new brain-computer interface that’s engineered to map a large area of the brain’s surface, in real time, at resolutions hundreds of times more detailed than typical arrays used in neurosurgical procedures.
A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies. The ultimate goal of a BCI is to restore function to patients with debilitating neurological conditions by enabling them to operate digital devices using only their thoughts.
The Layer 7 Cortical Interface, developed by Precision Neuroscience Corporation, contains 1,024 tiny electrodes spanning an area of 1.5 square centimeter, embedded in a flexible film that conforms to the brain’s surface. The film is one-fifth the thickness of a human hair and was designed to be implanted and removed by neurosurgeons without damaging brain tissue.
“Mount Sinai has established an international reputation for our ability to conduct the most advanced biomedical and scientific research, for our commitment to exceptional patient care, and for our entrepreneurial approach to generating new treatments and advancements in care,” said Joshua B. Bederson, MD, Chair of Neurosurgery at the Mount Sinai Health System and Co-Founder of Mount Sinai BioDesign. “This culture of excellence, innovation, and collaboration attracts some of the brightest and best clinicians and researchers in the world who are capable of rapidly translating research breakthroughs into new products and services that provide meaningful benefit to patients and our society. We are proud to be one of the leading sites participating in the trials for the new array and eager to see what we learn from the detailed information we will collect and analyze.”
As part of an open-label, single-arm feasibility study, Mount Sinai neurosurgeons are temporarily placing the investigational device on the surface of the study participants’ brains during intracranial procedures where surface mapping is routinely performed and correlated to evoked potentials (tests that measure the brain’s response to sensory stimulation) or standardized behavioral tasks that are routinely performed as part of these procedures. The device records high-resolution electrophysiological signals and the data collected is compared to that obtained using standard-of-care cortical surface arrays.
A team of Mount Sinai neuroscientists who have deep expertise in human electrophysiology will analyze and interpret the massive amount of data collected from the device. A secondary objective of the study is to assess the ability of the thin-film electrode to map electrophysiological correlates of awake behavioral tasks, including motor, speech, and cognitive tasks.
“Despite the vast complexity of activity across the human brain, standard monitoring tools can only capture a tiny fraction of the data we need—from a small handful of areas, or at very slow temporal resolution. This low-resolution data significantly limits our understanding of brain function and brain disorders,” says Ignacio Saez, PhD, Associate Professor of Neuroscience, and Neurosurgery, Director of the Human Neurophysiology Laboratory, and Principal Investigator of the trial at Icahn Mount Sinai. “The new device is exciting because it provides us with an extremely detailed depiction of electrical activity in the brain, capturing thousands of data points per second from a thousand brain sites in each participant. By monitoring neuronal activity at this unprecedented resolution, our interdisciplinary team at Mount Sinai hopes to gain important insights into how brain function supports behavior and is affected by disease states. Our ultimate goal is to obtain actionable knowledge that will open the door to new treatments for neurological and psychiatric disorders and improve quality of life for our patients.”
Precision Neuroscience was co-founded by Benjamin Rapoport, MD, PhD, Assistant Professor of Neurosurgery at Icahn Mount Sinai, a practicing neurosurgeon who has a PhD in electrical engineering and computer science. Dr. Rapoport also serves as the Scientific Director of Mount Sinai BioDesign, a medical technology prototyping center and incubator housed within the Mount Sinai Health System.
Dr. Rapoport is an equity owner in Precision Neuroscience and serves as their Chief Scientific Officer and a member of their board of directors. As a faculty member in the Department of Neurosurgery, he reports to Dr. Bederson. Neither Dr. Bederson nor Mount Sinai have a financial interest in Precision Neuroscience. All Precision Neuroscience research at Mount Sinai is conducted by independent investigators without financial ties to the company.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 13th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.
Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.
Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. The Health System includes approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses across seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, a school of nursing, and schools of medicine and graduate school of biomedical sciences.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York and recognized as one of the world’s top Smart Hospital by Newsweek. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools for National Institutes of Health (NIH) funding and No. 1 among freestanding medical schools, reflecting the strength of its scientific enterprise and leadership in biomedical research.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.